Pembrolizumab,Trastuzumab,Zolbetuximab,Nivolumab,Ipilimumab,Tislelizumab,oxaliplatin,capecitabine
Merck,Roche,astellas,BMS,Beigene
[]
here we go, the $alpmy zolbetuximab #gi23 late-breaking abstract is live 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.